Market Access Insights
Access the relevant market access data and insights you need on health plans, policy restrictions, PBMs, providers, and more
Formulary Advantages in Type 2 Diabetes: Impact of Current and Future DPP-IV Inhibitors and GLP-1 Analogues on Advantaged Reimbursement Status for Key Brands
Type 2 diabetes currently affects almost 24 million in the United States and the prevalence of the disease is set to grow at approximately 3% per year over the next five years. As biopharmaceutical co…